Drug Search Results
More Filters [+]

Danicopan

Alternative Names: danicopan, ach-0144471, ach0144471, ach 0144471, ach-4471, ach4471, ach 4471, ALXN-2040, ALXN2040, ALXN 2040
Latest Update: 2024-06-10
Latest Update Note: News Article

Product Description

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Danicopan is a first-in-class oral proximal, complement alternative pathway factor D (FD) inhibitor. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33121236/)

Mechanisms of Action: CFD Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Paroxysmal Nocturnal Hemoglobinuria *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Danicopan

Countries in Clinic: Australia, Brazil, Canada, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Latvia, Malaysia, Netherlands, New Zealand, Poland, Slovakia, Spain, Taiwan, Thailand, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Paroxysmal Hemoglobinuria|Paroxysmal Nocturnal Hemoglobinuria

Phase 2: Complement 3 Glomerulopathy|Geographic Atrophy|Glomerulonephritis, Membranoproliferative|Macular Degeneration

Phase 1: Breast Cancer|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031230248

P3

Recruiting

Paroxysmal Nocturnal Hemoglobinuria|Paroxysmal Hemoglobinuria

2027-02-26

ALXN2040-PNH-303

P3

Active, not recruiting

Paroxysmal Hemoglobinuria|Paroxysmal Nocturnal Hemoglobinuria

2027-01-31

70%

D7332C00006

P3

Not yet recruiting

Paroxysmal Hemoglobinuria|Paroxysmal Nocturnal Hemoglobinuria

2027-01-15

86%

2021-004253-22

P3

Active, not recruiting

Paroxysmal Hemoglobinuria|Paroxysmal Nocturnal Hemoglobinuria

2025-06-17

Recent News Events